Published in final edited form as:

Surg Obes Relat Dis. 2016 July ; 12(6): 1230–1235. doi:10.1016/j.soard.2016.05.008.

Mechanisms of Surgical Control of Type 2 Diabetes: GLP-1 is the Key Factor - Maybe

Marzieh Salehi¹ and David A. D'Alessio²

¹Cedars-Sinai Medical Center, Department of Biomedical Science, Los Angeles, CA

²Duke University, Department of Medicine, Durham, NC

Abstract

Bariatric operations are the most effective treatment for obesity and diabetes. The two most commonly performed weight-loss procedures, Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) improve glycemic control in patients with type 2 diabetes (T2D) independent of weight loss. One of the early hypotheses raised to explain the immediate anti-diabetic effect of RYGB was that rapid delivery of nutrients from the stomach pouch into the distal small intestine enhances enteroinsular signaling to promote insulin signaling. Given the 10-fold increase in post-meal glucagon like-peptide-1 (GLP-1) response compared to unchanged integrated levels of postprandial glucose-dependent insulintropic peptide (GIP) after RYGB, enhanced meal-induced insulin secretion after this procedure was thought to be the result of elevated glucose and GLP-1 levels. In this contribution to the larger point-counterpoint debate about the role of GLP-1 after bariatric surgery, most of the focus will be on RYGB.

Keywords

gastric bypass surgery; GLP-1; hyperinsulinemia; diabetes; hypoglycemia

The long-awaited reports of randomized clinical trials provided definitive evidence that weight-loss procedures induce diabetes remission [1–5]. This glycemic reducing effect of bariatric surgery is indeed due to better fasting insulin sensitivity as a result of surgically induced weight loss [6–8]. However, there is also clear evidence that some of the glycemic improvement after RYGB [9], and to a lesser degree, SG [10] is immediate and, therefore, weight-loss independent.

As early as one week after RYGB, meal-induced insulin secretion is increased, both in individuals with or without T2D [11]. This postprandial hyperinsulinemia is associated with

Corresponding author and the reprint requests should be addressed to: Marzieh Salehi, MD, MS, Cedars-Sinai Medical Center, Department of Biomedical Science, 8700 Beverly Blvd, Thalians E104, Los Angeles, CA 90048, Phone: (310)967-2779, Fax: (310) 967-3869, marzieh.salehi@cshs.org.

Conflict of interest: The authors have nothing to disclose

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

earlier and higher peaks of glucose as well as earlier and larger GLP-1 secretion [11–16]. As a result, subjects with RYGB have rapid clearance of glucose from the circulation and lower nadir glucose levels in the 60–90 minutes after eating. The glycemic profile of RYGB is exaggerated in a subgroup of individuals who develop postprandial hypoglycemia years after this procedure [17] in whom meal-induced hyper- and hypoglycemia are associated with larger insulin and GLP-1 secretion compared to those without symptomatic low glucose [18] (Fig. 1). Similar to RYGB, although to a lesser degree, SG increases GLP-1 responses to meal ingestion; [15, 19] whereas, other gastric bariatric procedures such as banding have no effect on postprandial glucose excursion or insulin and gut hormone responses [20]. Altogether these findings are suggestive of a continuum in altered islet function mediated by changes in enteroinsular axis activity as a result of RYGB or SG.

In individuals with a normal gastrointestinal tract, postprandial glucose homeostasis is tightly regulated by glucose-dependent gut hormones, mainly GLP-1 and glucose-dependent insulinotropic peptide (GIP), secreted in response to nutrient ingestion [21–24]. In addition, it is recognized that the post-meal glycemic excursion is determined by the rate of carbohydrate entrance into the small intestine and splanchnic glucose uptake. Gastric emptying *per se* accounts for about one third of the variance of glycemic response to 75 g glucose ingestion in both normal individuals and those with T2D [25, 26]. Direct infusion of glucose into the duodenum at varying rates within the normal range of gastric emptying (1–4 kcal/min) alters the glycemic response, as well as insulin and gut hormone secretion dose-dependently [27]. Therefore, a major factor in the distinct postprandial glycemic pattern after RYGB can be attributed to faster transit of nutrients from the small gastric pouch into the small intestine [28], likely causing the augmented secretion of incretins, mainly GLP-1. Increased rates of carbohydrate appearance in the small intestine results in a larger flux of splanchnic and systemic glucose [16, 29, 30]. Consequently, increased meal-induced insulin secretion after RYGB is partly due to augmented β -cell sensitivity to glucose, while insulin secretion to intravenous glucose infusion does not differ among individuals with and without RYGB [31–33]. Taken together, the combined effects of elevated glucose [29, 30, 34] and a larger incretin effect [13, 14, 32] appear to account for enhanced meal-induced insulin secretion after RYGB, while the role of the incretin effect after SG is yet to be defined.

Physiologic effects of endogenous GLP-1 on postprandial glucose metabolism in humans have been investigated using intravenous infusions of the potent GLP-1r antagonist, exendin-[9–39] (Ex-9) during meal tolerance test. However, elimination of GLP-1 action during meal ingestion results in relative hyperglycemia, which confounds the interpretation of the insulinotropic effects of endogenous GLP-1. To circumvent this problem we have infused Ex-9 during meal studies when glucose levels were maintained fixed with a hyperglycemic clamp. In this setting, we have shown that GLP-1r blockade suppresses postprandial insulin secretion and increased glucagon levels in both healthy individuals [22] and patients with well-controlled diabetes [21]. Extending these experiments to address the direct effect of endogenous GLP-1 on postprandial insulin secretion after RYGB, we found that the contribution of endogenous GLP-1 to meal-induced insulin secretion is twice as large in non-diabetic individuals with RYGB as in the body mass index (BMI) matched healthy controls [32] (Fig. 2). While subjects with RYGB had postprandial hyperglucagonemia compared to the non-surgical cohort, Ex-9 infusion suppressed glucagon secretion similarly

in both groups, demonstrating that the glucagonostatic effects of GLP-1 are not affected by RYGB [32]. This was the first evidence confirming that elevated plasma GLP-1 concentrations in people with RYGB are associated with increased GLP-1 action, e.g. meal-stimulated insulin release. Moreover, these results do not seem to be the result of changes in gastric emptying since the effect of Ex-9 infusion on the rate of nutrient passage from the gastric pouch to the small intestine was negligible [21, 22, 35].

Separate studies using Ex-9 infusion during meals without glucose clamps supported the initial experiments with GLP-1 blockade. Thus, blocking the GLP-1r had a larger incremental effect on the postprandial glycemic response in non-diabetic RYGB subjects compared to weight-matched controls without surgery ($37\pm12\%$ in GB vs. $14\pm12\%$ in controls); this was associated with a similar reduction of insulin secretion (13–14%) and β -cell glucose sensitivity (15–20%) in the two groups [18]. Using a comparable study design, another group of investigators observed similar findings, with Ex-9 infusion having a disproportionate effect to raise blood glucose in RYGB relative to control subjects (45% vs. 24%) [36]. Again the authors noted a relative reduction in β -cell glucose sensitivity in non-diabetic individuals after RYGB compared to the non-surgical cohort.

As the number of bariatric surgeries performed over the last decade has increased, it has become more apparent that a subgroup of individuals develop postprandial hypoglycemia several years after RYGB [37–39]. Hypoglycemia in affected individuals is exclusively postprandial, progressive, often associated with loss of consciousness or seizures, and only partially responsive to diet modification or available therapeutic options [40]. While the histologic correlate of this syndrome remains under debate [38, 41], it is recognized that this often-debilitating complication is associated with greater insulin and GLP-1 responses to meal ingestion compared to asymptomatic individuals after RYGB [37, 42] (Fig. 1), raising the possibility of a pathogenic role for GLP-1 in this syndrome. Using Ex-9 infusion, we have shown that blocking GLP-1r corrects hypoglycemia by suppressing insulin secretion in these patients [18] (Fig. 3). However, we also have found that systemic meal-derived glucose appearance is larger in subjects with the hypoglycemia syndrome than in asymptomatic individuals and not affected by blocking GLP-1r [18], suggestive that other pathogenic factors beyond GLP-1 contribute to hypoglycemia.

Together, these findings indicate that elimination of GLP-1 has a greater postprandial glycemic effect in non-diabetic individuals after RYGB and to larger degree in those with hyperinsulinemic hypoglycemia syndrome. However, the question remains as to whether improved post-meal glucose homeostasis in patients with T2D is attributable to augmented GLP-1 action.

Several preclinical studies using mouse models with GLP-1 receptor deletions raised questions as to the necessity of GLP-1 signaling in glycemic improvement after bariatric surgery. GLP-1 receptor knockout mice had similar weight loss and improved glucose tolerance compared to control animals after RYGB [43] and SG [44]. While these models provide a powerful and specific approach to eliminating GLP-1 action, a caveat in the interpretation of these studies is that animals with developmental gene deletions may develop compensatory mechanisms to accommodate their lifelong absence of GLP-1r

signaling. Nonetheless, these findings do raise some question as to the role of GLP-1 after surgery.

The relevance of GLP-1 action in glucose reducing effects of RYGB was investigated by three independent investigators using different methods. In the first study[45], 9 patients with T2D (average A1C of 6.5%) were studied with a meal tolerance test with and without GLP-1r blockade before RYGB, and 1 week and 3 months after surgery. Eight of 9 subjects who were treated with antidiabetic medications prior to RYGB (metformin alone or in combination with insulin secretagogues or insulin) required no medications after surgery with an average A1C reduction to 5.7% at 3 months. RYGB altered the glycemic response to meal ingestion, leading to an earlier peak and larger glucose excursion but no significant changes in the incremental $AUC_{\text{Glucose}(4\text{hr})}$. In parallel to glycemic changes post-meal insulin secretion was shifted to the left with greater β -cell glucose sensitivity after surgery. Blocking GLP-1r signaling resulted in a larger $AUC_{\text{Glucose}(4\text{hr})}$ throughout the experiment. This glycemic effect of Ex-9 was associated with suppression of insulin secretion as well as β -cell glucose sensitivity to levels similar to pre-operative at 1 week and 3 months, suggesting that the glycemic reducing effect of RYGB is partly due to an enhanced GLP-1-stimulated insulin response. Ex-9 increased glucagon and had no effect on gastric emptying as previously reported.

The second study [46] evaluated glucose and insulin response to meal ingestion with and without infusion of Ex-9 in 8 patients with resolved diabetes after RYGB (average A1C of 6.6% prior to GB) compared to 7 leaner non-diabetic healthy controls (average BMI: 31 kg/m^2 in RYGB vs. 21 kg/m^2 in controls). Individuals with history of RYGB had larger $AUC_{\text{Glucose}(2\text{hr})}$ values compared to the leaner controls. The relative enhancement in the integrated glucose levels measured for 2 hours ($AUC_{\text{Glucose}(2\text{hr})}$) as a result of Ex-9 infusion was similar in both groups (10%). The relative reduction in insulin secretion, on the other hand, was significantly larger in surgical subjects compared to non-surgical (decrease in $AUC_{\text{Insulin}(2\text{hr})}$: 54% vs. 4%), indicating that RYGB enhances GLP-1-induced insulin secretion.

In a more recent study [47] patients with T2D (average A1C of 7.5%) were studied with liquid mixed-meals with and without infusion of Ex-9 after 10% weight loss achieved by RYGB (N=8) or life style modification (N=8). The target weight loss was achieved in 2 months after RYGB and in 3 months in non-surgical groups, leading to improved glucose levels in both groups estimated by A1C (average of 6.4%). Despite similar A1C reduction, weight loss led to a larger reduction in the incremental $AUC_{\text{Glucose}(3\text{hr})}$ in the non-surgical cohort compared to those after RYGB (35% vs. 15%), likely due to an earlier and larger glycemic excursion after RYGB as a result of increased nutrient flux. Cross-sectional comparison of Ex-9 effect on postprandial glucose levels after weight loss, however, revealed an identical relative enhancement in $AUC_{\text{Glucose}(3\text{hr})}$ among surgical and non-surgical individuals (41% in RYGB vs. 44% in non-surgical). Despite similar changes in glycemia, the insulinotropic effects of endogenous GLP-1 were significantly greater after RYGB than the life style interventions (reduction in $AUC_{\text{C-peptide}(3\text{hr})}$: 37% in RYGB vs. 5% in non-surgical), consistent with findings from the previous studies. The absence of glycemic reducing effects of GLP-1r antagonist beyond the effect of weight loss in this

study is considered as an evidence against the beneficial effects of enhanced GLP-1 action in diabetes remission after RYGB despite the enhanced insulinotropic effects.

The enteroinsular axis in postprandial glucose homeostasis after SG is much less characterized, but SG seems to have similar effects on glucose, insulin, and GLP-1 responses to meal ingestion as RYGB [15], only smaller [19]. There is only one cross-sectional study that compares the integrated glucose and insulin responses to meal ingestion with and without Ex-9 infusion among 8 subjects with resolved diabetes after SG, 6 non-diabetic individuals after SG, and 8 leaner non-operated controls. Glycemic response to meal ingestion among groups were not similar as those with SG and history of diabetes had a larger $AUC_{Glucose(2hr)}$ at the time of evaluation compared to those non-diabetic subjects with SG or non-surgical individuals. The glycemic effect of GLP-1r antagonist was similar in both lean control and SG subjects with history of T2D whereas the non-diabetic SG individuals had minimal glycemic effect as a result of Ex-9 infusion. Along with glycemic data, β -cell glucose sensitivity was suppressed equally in both lean control and SG subjects with history of T2D (~35%) with no changes in SG non-diabetic subjects as a result of elimination of GLP-1 action. While the findings are not consistent with increased GLP-1 action after SG, further studies with alternative designs are needed to address this issue.

In summary, findings from clinical studies in humans support a significant role for enhanced contribution of endogenous GLP-1 to postprandial β -cell function and glycemic pattern after RYGB [32, 36, 45], and especially so in individuals with the hypoglycemia syndrome [18]. However, based on current data the enhanced GLP-1 action on insulin response after RYGB has no further beneficial effect on glucose improvement in patients with diabetes remission after RYGB [47]. It is important to note that there is no data for or against a role for increased GLP-1 action in relation to other components of the enteroinsular axis (i.e., nutrient and neural stimulation). Also there is little known about the inter-individual variability in sensitivity to GLP-1 among individuals undergoing weight loss operations. Such information will likely be critical for the development of novel approaches for treatment of diabetes as well as improvement of the glycemic effects of RYGB and SG in patients with partial diabetes remission or relapse after complete remission [1, 48].

Acknowledgments

Grant Support: National Institute of Health, DK105379 (MS), DK083554 (MS), and DK101991 (DD).

This work was supported by grants from National Institute of Health, DK105379 (MS), DK083554 (MS), and DK101991 (DD).

References

1. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. *N Engl J Med*. 2014; 370:2002–13. [PubMed: 24679060]
2. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. *N Engl J Med*. 2012; 366:1567–76. [PubMed: 22449319]
3. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and

- hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. *Jama*. 2013; 309:2240–9. [PubMed: 23736733]
4. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. *N Engl J Med*. 2012; 366:1577–85. [PubMed: 22449317]
 5. Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. *Diabetologia*. 2016
 6. Guldstrand M, Ahren B, Adamson U. Improved beta-cell function after standardized weight reduction in severely obese subjects. *Am J Physiol Endocrinol Metab*. 2003; 284:E557–65. [PubMed: 12556352]
 7. Villareal DT, Banks MR, Patterson BW, Polonsky KS, Klein S. Weight Loss Therapy Improves Pancreatic Endocrine Function in Obese Older Adults. *Obesity (Silver Spring)*. 2008
 8. Ferrannini E, Camastra S, Gastaldelli A, Maria Sironi A, Natali A, Muscelli E, et al. beta-cell function in obesity: effects of weight loss. *Diabetes*. 2004; 53(Suppl 3):S26–33. [PubMed: 15561918]
 9. Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. *Ann Surg*. 2000; 232:515–29. [PubMed: 10998650]
 10. Lee WJ, Chong K, Ser KH, Lee YC, Chen SC, Chen JC, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. *Arch Surg*. 2011; 146:143–8. [PubMed: 21339423]
 11. Jorgensen NB, Jacobsen SH, Dirksen C, Bojsen-Moller KN, Naver L, Hvolris L, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. *Am J Physiol Endocrinol Metab*. 2012; 303:E122–31. [PubMed: 22535748]
 12. Nannipieri M, Baldi S, Mari A, Colligiani D, Guarino D, Camastra S, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. *J Clin Endocrinol Metab*. 2013; 98:4391–9. [PubMed: 24057293]
 13. LaFerrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. *Diabetes Care*. 2007; 30:1709–16. [PubMed: 17416796]
 14. LaFerrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2008; 93:2479–85. [PubMed: 18430778]
 15. Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. *Obes Surg*. 2012; 22:740–8. [PubMed: 22354457]
 16. Jacobsen SH, Bojsen-Moller KN, Dirksen C, Jorgensen NB, Clausen TR, Wulff BS, et al. Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. *Diabetologia*. 2013; 56:2250–4. [PubMed: 23893303]
 17. Goldfine A, Mun E, Patti ME. Hyperinsulinemic hypoglycemic following gastric bypass surgery. *Curr Opin Endocrinol Diabetes*. 2006; 13:419–24.
 18. Salehi M, Gastaldelli A, D'Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. *Gastroenterology*. 2014; 146:669–80. e2. [PubMed: 24315990]
 19. Kashyap SR, Bhatt DL, Wolski K, Watanabe RM, Abdul-Ghani M, Abood B, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. *Diabetes Care*. 2013; 36:2175–82. [PubMed: 23439632]
 20. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. *Surg Obes Relat Dis*. 2007; 3:597–601. [PubMed: 17936091]

21. Salehi M, Aulinger B, Prigeon RL, D'Alessio DA. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. *Diabetes*. 2010; 59:1330–7. [PubMed: 20215429]
22. Salehi M, Vahl TP, D'Alessio DA. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. *J Clin Endocrinol Metab*. 2008; 93:4909–16. [PubMed: 18827000]
23. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. *Gut*. 2006; 55:243–51. [PubMed: 15985560]
24. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. *Regul Pept*. 2003; 114:115–21. [PubMed: 12832099]
25. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. *Diabetologia*. 1993; 36:857–62. [PubMed: 8405758]
26. Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L. Gastric emptying in early noninsulin-dependent diabetes mellitus. *J Nucl Med*. 1996; 37:1643–8. [PubMed: 8862300]
27. Ma J, Pilichiewicz AN, Feinle-Bisset C, Wishart JM, Jones KL, Horowitz M, et al. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. *Diabet Med*. 2012; 29:604–8. [PubMed: 22004512]
28. Nguyen NQ, Debrececi TL, Bambrick JE, Bellon M, Wishart J, Standfield S, et al. Rapid gastric and intestinal transit is a major determinant of changes in blood glucose, intestinal hormones, glucose absorption, and postprandial symptoms after gastric bypass. *Obesity (Silver Spring)*. 2014
29. Camastra S, Muscelli E, Gastaldelli A, Holst JJ, Astiarraga B, Baldi S, et al. Long-term effects of bariatric surgery on meal disposal and beta-cell function in diabetic and nondiabetic patients. *Diabetes*. 2013; 62:3709–17. [PubMed: 23835342]
30. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. *Obesity (Silver Spring)*. 2008; 16:298–305. [PubMed: 18239636]
31. Dutia R, Brakoniecki K, Bunker P, Paultre F, Homel P, Carpentier AC, et al. Limited recovery of beta-cell function after gastric bypass despite clinical diabetes remission. *Diabetes*. 2013
32. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. *Diabetes*. 2011; 60:2308–14. [PubMed: 21868791]
33. Camastra S, Gastaldelli A, Mari A, Bonuccelli S, Scartabelli G, Frascerra S, et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. *Diabetologia*. 2011; 54:2093–102. [PubMed: 21614570]
34. Salehi M, Gastaldelli A, D'Alessio DA. Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion. *Diabetologia*. 2014
35. Nicolaus M, Brodl J, Linke R, Woerle HJ, Goke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. *J Clin Endocrinol Metab*. 2011; 96:229–36. [PubMed: 21047924]
36. Shah M, Law JH, Micheletto F, Sathananthan M, Dalla Man C, Cobelli C, et al. Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. *Diabetes*. 2014; 63:483–93. [PubMed: 24089513]
37. Goldfine AB, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. *J Clin Endocrinol Metab*. 2007; 92:4678–85. [PubMed: 17895322]
38. Service FJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. *N Engl J Med*. 2005; 353:249–54. [PubMed: 16034010]

39. Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. *Diabetologia*. 2005; 48:2236–40. [PubMed: 16195867]
40. Vella A, Service FJ. Incretin hypersecretion in post-gastric bypass hypoglycemia--primary problem or red herring? *J Clin Endocrinol Metab*. 2007; 92:4563–5. [PubMed: 18056781]
41. Meier JJ, Butler AE, Galasso R, Butler PC. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. *Diabetes Care*. 2006; 29:1554–9. [PubMed: 16801578]
42. Salehi M, Gastaldelli A, D'Alessio DA. Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia. *J Clin Endocrinol Metab*. 2014; 99:2008–17. [PubMed: 24617664]
43. Mokadem M, Zechner JF, Margolskee RF, Drucker DJ, Aguirre V. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. *Mol Metab*. 2014; 3:191–201. [PubMed: 24634822]
44. Wilson-Perez HE, Chambers AP, Ryan KK, Li B, Sandoval DA, Stoffers D, et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. *Diabetes*. 2013; 62:2380–5. [PubMed: 23434938]
45. Jorgensen NB, Dirksen C, Bojsen-Moller KN, Jacobsen SH, Worm D, Hansen DL, et al. Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved beta-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes. *Diabetes*. 2013; 62:3044–52. [PubMed: 23649520]
46. Jimenez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 Action and Glucose Tolerance in Subjects With Remission of Type 2 Diabetes Mellitus After Gastric Bypass Surgery. *Diabetes Care*. 2013
47. Vetter ML, Wadden TA, Teff KL, Khan ZF, Carvajal R, Ritter S, et al. GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification. *Diabetes*. 2015; 64:434–46. [PubMed: 25204975]
48. Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. *Obes Surg*. 2013; 23:93–102. [PubMed: 23161525]

Figure 1.

Blood glucose (A), GLP-1 (B), and insulin (C) responses to meal ingestion in individuals after RYGB with (Sym, solid black line and closed square) and without (Asym, dashed line and open square) previous history of postprandial hypoglycemia, and non-surgical healthy controls (CON, grey solid line and closed square)[42]

Figure 2. Relative increase in meal-induced insulin secretion rate (ISR), and endogenous GLP-1 contribution to ISR (B) in the individuals after RYGB (black bar) and the BMI-matched healthy controls (white bar). * $p < 0.05$ compared to GB[32]

Figure 3.

Blood glucose (A) and insulin secretion (B) responses to meal ingestion in individuals with post-RYGB hyperinsulinemic hypoglycemia syndrome (left panels) and asymptomatic individuals after RYGB (right panels) during meal studies with (dashed line and open circle) and without (solid line and open circle) Ex-9 infusion[18]